AR and breast carcinoma: Using a genomic assay for AR expression (PREDICT AR+), 56 patients with a positive PREDICT AR assay had a clinical benefit rate of 39% at 16 weeks, and a median PFS of 16.1 weeks.25 A third study evaluated seviteronel, a selective CYP17 lyase and AR inhibitor in advanced breast cancer, including TNBC, demonstrating the initial safety and efficacy in TNBC (2 patients with clinical benefit at 4 months).27 These findings suggest potential value for therapies targeted to AR.